Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Table 3 Treatment information on fecal microbiota transplantation, summarised for all studies

Indication	First author	Year	Pre-treatment with bowel lavage? (Y/N)	Route of administration1	Number of transplantations (n)	Amount of fresh stool per treatment (mL/g/tablespoons)	Suspension infused(cc or mL)	Donor2	ae (n)	Withdrawal due to ae (n)	Ae potentially associated with fmt3 (n)	Sae (n)
CDI	Aas	2003	NM	U	1	30 g	NM	G and O	0	0	0	24
	Arkkila	2010	Y	C	1-2	20-30 mL	NM	G or H? and O	NM	NM	0	14
	Aroniadis	2013	NM	NM	1-2	NM	NM	NM	NM	NM	0	14
	Bansal	2013	NM	U and C	NM	NM	NM	G or H? and O	NM	NM	NM	NM
	Bobo	2013	NM	U and Ce	1-2	NM	NM	NM	NM	NM	NM	NM
	Borody	2013	NM	NM	1-42	NM	NM	NM	0	0	0	0
	Bowden	1981	N	Ce and U	1	NM	NM	H and O	0	0	0	34
	Brandt	2012	NM	C	1	NM	300-700 cc infused	G and H and O	0	0	0	0
	Byrne	2008	N	Ce	1-3	300-500 g	NM	G and H and O	4	0	0	0
	Eisman	1958	N	Ce	4	NM	NM	O	0	0	0	0
	Elopre	2013	NM	U	1	NM	NM	G	0	0	0	0
	Fischer	2013	Y	C	1-2	NM	NM	O	0	0	0	0
	Garborg	2010	N	U or C	1	50-100 g	NM	G and H and O	0	0	0	54
	Hamilton	2012	Y	C	1-2	50 g	NM	G and H and O	155	0	0	0
	Ihunnah	2013	NM	NM	1-2	NM	NM	NM	5	NM	0	24 , 86
	Jorup-Rönström	2012	NM	Ce	1-3	30 cc suspension	30 cc suspension	O	0	0	0	0
	Kassam	2010	N	Ce	1-2	NM	NM	NM	0	0	0	0
	Kelly	2012	Y	C	1	6-8 tablespoons	NM	R	0	0	0	0
	Khanna	2013	NM	C	1	50 g	NM	NM	0	0	0	0
	Louie	2013	Y	U	24-34 caps	50 g	NM	R	NM	NM	NM	NM
	MacConnachie	2009	N	U	1	30 g	NM	O	0	0	0	NM
	Mattila	2012	Y	C	1	20-30 mL	100 mL suspension	G and H and O	0	0	0	144
	Mellow	2010	NM	C	1	NM	NM	NM	0	0	0	34
	Miller	2010	NM	C	1	NM	NM	G and H	NM	0	NM	NM
	Neelakanta	2011	NM	C	1	pt 1: 250 g, pt2: NM	NM	G or H	NM	NM	NM	NM
	Newton	2013	NM	NM	NM	NM	NM	NM	NM	NM	NM	34
	Potakamuri	2013	NM	NM	1-5	NM	NM	NM	NM	NM	NM	2 (14, 16)
	Rohlke	2010	Y	C	1	NM	200-350 mL infused	G and H and O	NM	NM	NM	NM
	Rubin	2013	N	U	1	25 mL	NM	O	0	0	0	0
	Shiekh Sroujieh	2012	NM	U or C	1	30-50 g	NM	NM	0	0	0	0
	Silverman	2010	N	Ce	1-2	50 mL	NM	G and H	47	0	0	0
CDI	Van Nood	2013	Y	U	1-2	> 50 g	NM	G and H and O	15'	0	158	16
	Yoon	2010	NM	C	1	NM	NM	G and H	0	0	0	0
	Youngster	2013	NM	U or C	1-2	NM	NM	NM	0	NM	0	NM
IBD	Angelberger	2013	Y	U and Ce	3	NM	23.8 g (16.7-25)U, 20 g (6-21.7)C	O	5	0	29	0
	Greenberg	2013	NM	U or C + Ce	> 1	NM	NM	NM	3	0	0	0
	Borody	2012	NM	NM	NM	NM	NM	NM	NM	NM	NM	0
	Kump	2013	NM	C	2-5	NM	NM	O	NM	0	NM	0
	Kump	2013	Y	C	1	100-150 g	NM	O	1	0	110	0
	Kunde	2013	N	Ce	511	90 g (70-113)	NM	G and O	9	112	210	0
	Vermeire	2012	Y	U	3	200 g	NM	NM	3	0	310	0
IBS	Pinn	2013	NM	NM	1-3	NM	NM	NM	NM	NM	NM	NM
Pouchitis	Landy	2013	N	U	1	30 g	NM	NM	NM	NM	NM	NM
Constipation	Borody	2001	Y	Ce	5-14	NM	NM	NM	NM	NM	NM	NM
Metabolic syndrome	Vrieze	2012	Y	U	1	NM	NM	O	NM	NM	NM	NM

¹Route of administration: Upper GI tract (U), colon (C) or colon per enema (Ce);

²Genetic related (G), sharing the same household (H) or other (O);

³Perforation, post-transplant spesis/ bacteriemia/ transmission of communicable diseases;

⁴Death, both unrelated and related;

⁵Some irregularity of bowel movements and excessive flatulence during the first couple of weeks following the procedure;

⁶Hospitalised;

⁷Post infectious IBS (1). antibiotic treatment for urinary tract infections (2). Antibiotics for perioperative prophylaxis of a hip replacement (1). None of these 3 patients relapsed with CDI despite the antibiotic therapy;

⁸(94%) had diarrhea, cramping (31%) and belching (19%): symptoms resolved within 3 h. During FU 3 patients who were treated with donor feces (19%) had constipation; ⁹Fever: blood cultures were taken, but no bacterial pathogen was detectable (2);

¹⁰Fever;

¹¹Intolerance with immediate leaking of enemas for 3 consecutive days;

¹²Daily for 5 d. NM: Not mentioned; IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome.